- Home
- LDP vs ERAS Comparison
LDP vs ERAS Comparison
Compare LDP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- ERAS
- Stock Information
- Founded
- LDP 2012
- ERAS 2018
- Country
- LDP United States
- ERAS United States
- Employees
- LDP N/A
- ERAS N/A
- Industry
- LDP Finance Companies
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- ERAS Health Care
- Exchange
- LDP Nasdaq
- ERAS Nasdaq
- Market Cap
- LDP 607.2M
- ERAS 719.0M
- IPO Year
- LDP N/A
- ERAS 2021
- Fundamental
- Price
- LDP $20.90
- ERAS $2.67
- Analyst Decision
- LDP
- ERAS Strong Buy
- Analyst Count
- LDP 0
- ERAS 5
- Target Price
- LDP N/A
- ERAS $6.10
- AVG Volume (30 Days)
- LDP 102.5K
- ERAS 1.7M
- Earning Date
- LDP 01-01-0001
- ERAS 11-12-2024
- Dividend Yield
- LDP 7.91%
- ERAS N/A
- EPS Growth
- LDP N/A
- ERAS N/A
- EPS
- LDP N/A
- ERAS N/A
- Revenue
- LDP N/A
- ERAS N/A
- Revenue This Year
- LDP N/A
- ERAS N/A
- Revenue Next Year
- LDP N/A
- ERAS N/A
- P/E Ratio
- LDP N/A
- ERAS N/A
- Revenue Growth
- LDP N/A
- ERAS N/A
- 52 Week Low
- LDP $16.16
- ERAS $1.51
- 52 Week High
- LDP $20.30
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- LDP 41.58
- ERAS 43.56
- Support Level
- LDP $20.77
- ERAS $2.59
- Resistance Level
- LDP $21.70
- ERAS $3.19
- Average True Range (ATR)
- LDP 0.28
- ERAS 0.20
- MACD
- LDP -0.02
- ERAS -0.02
- Stochastic Oscillator
- LDP 13.44
- ERAS 20.13
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.